BioMarin Pharmaceutical (BMRN) News Today

Covea Finance lifted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 328.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 77,100 shares of the biotechnology compa

Raymond James reaffirmed an "outperform" rating and issued a $79.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday.

Sanctuary Advisors LLC purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,043 shares of the bio

NewEdge Advisors LLC grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 3,931.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,885 shares of the biotechnology compa

AQR Capital Management LLC grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 144.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 55,372 shares of the biotechnology company's stock after buying an

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twenty-one analysts that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rati

Royal Bank of Canada reduced their target price on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a "sector perform" rating on the stock in a report on Friday.

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

The Manufacturers Life Insurance Company increased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 177.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 180,617 shares of the biotechnology company's stock af

Teachers Retirement System of The State of Kentucky raised its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 17.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 194,207 shares of

MBB Public Markets I LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,991 shares of the biotechnology company's stoc

Novo Holdings A S raised its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 8.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 490,000 shares of the biotechnology c

Susquehanna Fundamental Investments LLC acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 68,346 shares of the

Lighthouse Investment Partners LLC acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 63,000 shares of the biotechnology company's stock, valued at approximately $5

Deerfield Management Company L.P. Series C bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 9,832 shares of the biotechnology compa

DeepCurrents Investment Group LLC decreased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 13.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 117,182 shares of the biotechnology company's stock after selling 1

Troluce Capital Advisors LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 71,600 shares of the biotechnology company's sto

BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 1-Year Low at $68.73

Hsbc Holdings PLC lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 61.4% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 89,795 shares of the biotechnology company's stock after selling 142,903 shares during the p

Avoro Capital Advisors LLC boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 4.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,557,416 shares of

Ameritas Investment Partners Inc. bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 40,387 shares of the biotechnology co

Federated Hermes Inc. purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 20,167 shares of the biotechnology company's stoc

Amalgamated Bank lifted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 792.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 95,922 shares of the biotechnology company's stock after acquiring an additional

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Equities researchers at Zacks Research increased their Q1 2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a note issued to investors on Monday, September 16th. Zacks Research analyst S. Ganoria now expects that

E Fund Management Co. Ltd. increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 167.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,480 shares of the biotechnology company

Texas Permanent School Fund Corp acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,646 shares of th

Scotiabank reduced their price target on BioMarin Pharmaceutical from $95.00 to $78.00 and set a "sector perform" rating for the company in a research report on Tuesday.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling 5,850,000 shares, a drop of 12.0% from the August 15th total of 6,650,000 shares. Based on an average daily trading volume, of 2,240,000 shares, the short-interest ratio is currently 2.6 days.

Primecap Management Co. CA boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 0.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,790,085 shares of the biotechnology company's stock after buying an a